Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient (or patient's legally acceptable representative) capable to provide a written, dated, and signed informed consent prior to any study related procedure~* Non-infected delayed-union fracture of a long bone of minimum 3 months and maximum 7 months (+/- 2 weeks)~Exclusion Criteria:~* Fracture interline larger than 2.5 cm~* Insufficient fracture stability~* Multifocal fracture~* Positive serology for hepatitis B, hepatitis C, Human Immunodeficiency Virus (HIV)~* Current or past medical disease that could interfere with the evaluation of the safety and efficacy, as judged by the investigator~* Severe renal or hepatic impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ALLOB® Implantation (Type: EXPERIMENTAL): One arm: ALLOB® Implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).